SynthesisLung2013
The association between TP53 Arg72Pro polymorphism and lung cancer susceptibility: evidence from 30,038 subjects.
Synthesis in Lung, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Article
- Article
- TP53 codon 72 Polymorphism and bladder cancer risk: a meta-analysis and emphasis on the role of tumor or smoking status.Journal of Cancer · 2018Article
- Comparative Transcriptome Profiling Reveals Coding and Noncoding RNA Differences in NSCLC from African Americans and European Americans.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Enhancement of Proliferation and Invasion of Gastric Cancer Cell by KDM5C Via Decrease in p53 Expression.Technology in cancer research & treatment · 2017Article
- TP53 Arg72Pro, mortality after cancer, and all-cause mortality in 105,200 individuals.Scientific reports · 2017Article
- JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- The TP53 codon 72 Pro/Pro genotype may be associated with an increased lung cancer risk in North China: an updated meta-analysis.International journal of clinical and experimental medicine · 2015Review
- Polymorphisms in TP53 are associated with risk and survival of osteosarcoma in a Chinese population.International journal of clinical and experimental pathology · 2015Article
- Lung cancer risk in relation to TP53 codon 47 and codon 72 polymorphism in Bangladeshi population.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Genetic variation in the TP53 pathway and bladder cancer risk. a comprehensive analysis.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe TP53 codon 72 polymorphism has been associated with the individual susceptibility to lung cancer. However, the association remains uncertain and varies with ethnicity, smoking status, cancer histology, and stage.
methodsWe performed a meta-analysis to evaluate the relationship between TP53 Arg72Pro polymorphism and lung cancer susceptibility basing on 15,647 lung cancer patients and 14,391 controls from 36 published literatures. We also performed stratified analysis in populations of different ethnicities, smoking statuses, lung cancer stages, and histological types.
resultsThe analysis showed a significantly increased lung cancer susceptibility among Pro allele carriers (P < 0.001, odds ratio (OR) = 1.14, 95% confidence interval (CI) = 1.1-1.19), especially for smokers (P < 0.001, OR = 1.29, 95% CI = 1.12-1.47). Stratified analysis indicated that Pro72 elevates lung cancer susceptibility in Asians, while it has no effect on lung cancer risk of Caucasians. Moreover, Pro carriers present an increased risk of developing squamous cell carcinoma and adenocarcinoma, instead of large cell carcinoma and small cell carcinoma. Interestingly, patients with the Pro allele seemed to be diagnosed with lung cancer at the early stages (stage I-II, P = 0.008, OR = 1.2, 95% CI = 1.05-1.37).
conclusionsOur results suggest that the Pro allele acts as a risk factor for development of lung cancer, especially for smokers and Asians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.